These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study. Hunninghake DB; Knopp RH; Schonfeld G; Goldberg AC; Brown WV; Schaefer EJ; Margolis S; Dobs AS; Mellies MJ; Insull W Atherosclerosis; 1990 Nov; 85(1):81-9. PubMed ID: 2126437 [TBL] [Abstract][Full Text] [Related]
65. Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Bhatnagar D; Durrington PN; Kumar S; Mackness MI; Dean J; Boulton AJ Diabetes; 1995 Apr; 44(4):460-5. PubMed ID: 7698516 [TBL] [Abstract][Full Text] [Related]
66. Effect of cyclosporine on HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions. Vaziri ND; Liang K; Azad H J Pharmacol Exp Ther; 2000 Aug; 294(2):778-83. PubMed ID: 10900260 [TBL] [Abstract][Full Text] [Related]
67. Acute effects of HMG-CoA reductase inhibitors on biliary lipids in patients with interrupted enterohepatic circulation. Muraca M; Baggio G; Miconi L; Vilei MT; Martini S; Gabelli C; Belluco C; Lise M; Crepaldi G Eur J Clin Invest; 1991 Apr; 21(2):204-8. PubMed ID: 1905632 [TBL] [Abstract][Full Text] [Related]
68. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Ellen RL; McPherson R Am J Cardiol; 1998 Feb; 81(4A):60B-65B. PubMed ID: 9526816 [TBL] [Abstract][Full Text] [Related]
69. Cholesterol and fatty acid metabolism in piglets fed sow milk or infant formula with or without addition of cholesterol. Rioux FM; Innis SM Metabolism; 1993 Dec; 42(12):1552-9. PubMed ID: 8246769 [TBL] [Abstract][Full Text] [Related]
70. Effects of pravastatin on cholesterol metabolism of cholesterol-fed heterozygous WHHL rabbits. Harsch M; Gebhardt A; Reymann A; Lang G; Schliack M; Löser R; Braesen JH; Niendorf A Br J Pharmacol; 1998 May; 124(2):277-82. PubMed ID: 9641543 [TBL] [Abstract][Full Text] [Related]
71. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mortensen SA; Leth A; Agner E; Rohde M Mol Aspects Med; 1997; 18 Suppl():S137-44. PubMed ID: 9266515 [TBL] [Abstract][Full Text] [Related]
72. HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure. Liang K; Kim CH; Vaziri ND Am J Physiol Renal Physiol; 2005 Mar; 288(3):F539-44. PubMed ID: 15507547 [TBL] [Abstract][Full Text] [Related]
73. Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III. Ghosh Laskar M; Eriksson M; Rudling M; Angelin B J Intern Med; 2017 Jun; 281(6):575-585. PubMed ID: 28145001 [TBL] [Abstract][Full Text] [Related]
75. Hepatic metabolism of cholesterol in Crohn's disease. Effect of partial resection of ileum. Akerlund JE; Reihnér E; Angelin B; Rudling M; Ewerth S; Björkhem I; Einarsson K Gastroenterology; 1991 Apr; 100(4):1046-53. PubMed ID: 2001802 [TBL] [Abstract][Full Text] [Related]
76. Unexpected inhibition of cholesterol 7 alpha-hydroxylase by cholesterol in New Zealand white and Watanabe heritable hyperlipidemic rabbits. Xu G; Salen G; Shefer S; Ness GC; Nguyen LB; Parker TS; Chen TS; Zhao Z; Donnelly TM; Tint GS J Clin Invest; 1995 Apr; 95(4):1497-504. PubMed ID: 7706454 [TBL] [Abstract][Full Text] [Related]
77. Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: reduced activity of cholesterol 7 alpha-hydroxylase. Ståhlberg D; Reihnér E; Rudling M; Berglund L; Einarsson K; Angelin B Hepatology; 1995 Apr; 21(4):1025-30. PubMed ID: 7705775 [TBL] [Abstract][Full Text] [Related]
78. Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell lines. Gebhardt A; Niendorf A J Cancer Res Clin Oncol; 1995; 121(6):343-9. PubMed ID: 7797599 [TBL] [Abstract][Full Text] [Related]
79. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats. Hooiveld GJ; Vos TA; Scheffer GL; Van Goor H; Koning H; Bloks V; Loot AE; Meijer DK; Jansen PL; Kuipers F; Müller M Gastroenterology; 1999 Sep; 117(3):678-87. PubMed ID: 10464145 [TBL] [Abstract][Full Text] [Related]
80. Hepatic fatty acid metabolism as a determinant of plasma and liver triacylglycerol levels. Studies on tetradecylthioacetic and tetradecylthiopropionic acids. Asiedu DK; al-Shurbaji A; Rustan AC; Björkhem I; Berglund L; Berge RK Eur J Biochem; 1995 Feb; 227(3):715-22. PubMed ID: 7867630 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]